Press Releases

03.17.2017

DILIsym Services, Inc. Evaluates Prospective NAFLD Treatment, Utilizing Its Flagship Technology in Collaboration with Pfizer, Inc.

03.17.2017

Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation

03.15.2017

Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

03.08.2017

Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

03.08.2017

The Union for International Cancer Control and Pfizer Announce Next Phase of Global Grants Initiative Supporting Metastatic Breast Cancer Patients

03.06.2017

Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

03.06.2017

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

03.01.2017

Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency

02.28.2017

Pfizer Prices €4,000,000,000 Debt Offering

02.28.2017

Pfizer Commits $4M to North Carolina Biotechnology Center Gene Therapy Fellowship Program

02.28.2017

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

02.28.2017

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review